<DOC>
	<DOCNO>NCT00115050</DOCNO>
	<brief_summary>This open-label safety study provide early access TMC114 HIV-1 infect patient fail exhaust regimen base commercially available antiretroviral ( ARV ) therapy ineligible participation Tibotec-sponsored trial .</brief_summary>
	<brief_title>TMC114-C209 : A Study Safety TMC114 With Low Dose Ritonavir ( RTV ) Other Antiretrovirals Experienced HIV-1 Infected Patients With Limited Treatment Options</brief_title>
	<detailed_description>This open-label non-randomized safety study provide early access TMC114 HIV-1 infect patient fail exhaust regimen base commercially available antiretroviral ( ARV ) therapy ineligible participation Tibotec-sponsored trial . The safety tolerability TMC114 combination low dose ritonavir ( RTV ) ARVs highly ARV-experienced HIV-1 infect patient limited treatment option assess . Treatment continue treatment-limiting toxicity , lose follow-up , withdrawal , pregnancy , discontinuation TMC114 development TMC114 commercially available patient . Total daily dose 600 mg TMC114 twice daily , intake combination one capsule 100 mg Ritonavir . Since TMC114 formulate 300mg tablet ( F014 ) mean 2X2 tablet per day , take orally . Treatment continue treatment-limiting toxicity , lose follow-up , withdrawal , pregnancy , discontinuation TMC114 development TMC114 commercially available patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patient voluntarily sign informed consent initiation study procedure Patient document HIV1 infection Patient limit treatment option multiple treatment failure Negative pregnancy test female childbearing potential CD4 cell count &lt; = 100 cells/mmÂ³ Viral load &gt; = 10,000 copies/mL . Primary HIV infection , patient eligible Tibotecsponsored trial Prior current participation trial TMC114 ( except Phase I study conduct HIVinfected patient ) Use disallow concomitant therapy Use investigational medication trial within last 90 day Female patient pregnant breast feed child bear potential without use effective nonhormonal birth control method willing continue practice birth control method screen last trialrelated activity Patients previously demonstrate clinically significant allergy hypersensitivity excipients investigational medication ( TMC114 ) Patients laboratory abnormality define standardized grade scheme base Division AIDS ( DAIDS ) table ( update version December 2004 ) Any grade 3 4 toxicity follow exception : Patients preexist diabetes asymptomatic glucose elevation grade 3 4 Patients asymptomatic triglyceride elevation grade 3 4 , patient clinical laboratory evidence active liver disease , liver impairment/dysfunction cirrhosis irrespective liver enzyme level Note : Patients coinfected chronic hepatitis B C allow enter trial condition clinically stable . Patients diagnose acute viral hepatitis screening allow enroll .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>TMC114</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Safety , TMC114-C209</keyword>
</DOC>